Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
526.1 INR | -2.32% | +4.16% | +3.44% |
14/05 | Transcript : Jubilant Ingrevia Limited, Q4 2024 Earnings Call, May 14, 2024 | |
14/05 | Jubilant Ingrevia Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.53 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.44% | 1.03B | B | ||
+17.80% | 66.43B | A- | ||
+2.92% | 49.89B | A- | ||
+19.98% | 41.88B | B+ | ||
+20.88% | 26.48B | A- | ||
+12.04% | 19.68B | C+ | ||
+1.27% | 17B | B+ | ||
-22.98% | 16.12B | A- | ||
+2.77% | 15.28B | B+ | ||
-9.25% | 15.18B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JUBLINGREA Stock
- Ratings Jubilant Ingrevia Limited